Synergy Asset Management LLC Makes New $33,000 Investment in IQVIA Holdings Inc. (NYSE:IQV)

Synergy Asset Management LLC purchased a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 169 shares of the medical research company’s stock, valued at approximately $33,000.

A number of other large investors have also recently modified their holdings of the company. Northwestern Mutual Wealth Management Co. grew its position in shares of IQVIA by 8.4% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 10,252 shares of the medical research company’s stock worth $2,168,000 after buying an additional 795 shares in the last quarter. Cetera Investment Advisers lifted its stake in IQVIA by 3.3% in the second quarter. Cetera Investment Advisers now owns 71,602 shares of the medical research company’s stock worth $15,140,000 after acquiring an additional 2,272 shares during the period. Sanctuary Advisors LLC bought a new position in IQVIA during the 2nd quarter worth about $803,000. Centaurus Financial Inc. raised its holdings in shares of IQVIA by 80.6% in the 2nd quarter. Centaurus Financial Inc. now owns 3,023 shares of the medical research company’s stock valued at $639,000 after purchasing an additional 1,349 shares in the last quarter. Finally, Mattson Financial Services LLC purchased a new stake in shares of IQVIA in the 2nd quarter worth approximately $1,028,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the stock. William Blair reissued an “outperform” rating on shares of IQVIA in a research note on Wednesday, December 11th. Truist Financial reduced their price target on IQVIA from $265.00 to $261.00 and set a “buy” rating for the company in a research report on Thursday, December 12th. Evercore ISI dropped their price objective on IQVIA from $270.00 to $265.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. Stephens started coverage on shares of IQVIA in a report on Friday, December 20th. They issued an “overweight” rating and a $250.00 target price for the company. Finally, JPMorgan Chase & Co. lowered their price target on shares of IQVIA from $279.00 to $240.00 and set an “overweight” rating on the stock in a report on Tuesday, November 5th. Four research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $255.71.

IQVIA Trading Down 0.2 %

IQVIA stock opened at $201.34 on Friday. IQVIA Holdings Inc. has a 52 week low of $187.62 and a 52 week high of $261.73. The stock has a 50-day moving average price of $200.42 and a 200 day moving average price of $220.65. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76. The company has a market capitalization of $36.54 billion, a price-to-earnings ratio of 26.42, a price-to-earnings-growth ratio of 2.12 and a beta of 1.48.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.